Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways

Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways

Dina S El-Agamy,1,2 Khaled M El-Harbi,3 Saad Khoshhal,3 Nishat Ahmed,1 Mohamed A Elkablawy,4,5 Ahmed A Shaaban,2,6 Hany M Abo-Haded3,7 1Department of Pharmacology and Toxicology, College of Pharmacy, Taibah University, Al-Madinah Al-Munawwarah 30001, Saudi Arabia; 2Department of Pharmacology and Tox...

Full description

Bibliographic Details
Main Authors: El-Agamy DS, El-Harbi KM, Khoshhal S, Ahmed N, Elkablawy MA, Shaaban AA, Abo-Haded HM
Format: Article
Language:English
Published: Dove Medical Press 2018-12-01
Series:Cancer Management and Research
Subjects:
Doxorubicin
Pristimerin
Cardiotoxicity
Nrf2
MAPK/NF-κB
Online Access:https://www.dovepress.com/pristimerin-protects-against-doxorubicin-induced-cardiotoxicity-and-fi-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/pristimerin-protects-against-doxorubicin-induced-cardiotoxicity-and-fi-peer-reviewed-article-CMAR

Similar Items